Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells
NCT04061746Phase 1Active, not recruiting
- Sponsor
- Medical University of South Carolina
- Start
- Feb 2020
- Primary completion
- May 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised trial of mesenchymal stem cells in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Medical University of South Carolina. Primary endpoint: Change in C-peptide area under the curve after a 2-hour MMTT. Started Feb 2020; status: active, not recruiting.
02
Drugs
mesenchymal stem cells
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04061746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04061746.